Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.

ABSTRACT:

SUBMITTER: Thomas S 

PROVIDER: S-EPMC6689178 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature